Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Thumbnail

Movers & Shakers: CEO changes at Johns Hopkins/UMMS, Central Health

Welcome to Movers & Shakers, a roundup of the latest executive movement in the healthcare industry, featuring two CEO moves at Mt. Washington Pediatric Hospital and Central Health.

 

Thumbnail

Political climate leads to loss of labor and delivery services

Bonner General Health, based in Sandpoint, Idaho, alerted the public about the upcoming discontinuation of labor and delivery services.

29 radiology societies met to discuss the specialty’s most pressing problems: 8 takeaways

“Of these, the mismatch between the clinical workload and the available radiologist workforce was foremost," experts wrote in JACR

Thumbnail

Jury absolves radiologist in $10M alleged malpractice case

The estate of a 41-year-old Virginia man claimed that radiologist Thomas Zumsteg missed signs of an aortic dissection on CT.

board room table trustee directors

Rayus Radiology leader becomes RBMA board president, plus more company news

Also, Ohio's largest radiology practice names a new leader, and Envision Healthcare misses a key financial filing deadline. 

SCAI blasts Medicare payment cuts to cardiology, asks members to take action

The group hopes its members can increase congressional support of a new bill introduced in the House. 

artificial intelligence robot evaluates healthcare data

ChatGPT answers straightforward cardiology questions, but struggles with complex cases

The popular chat-based AI model was able to answer straightforward questions with considerable accuracy. However, it still has certain issues that need to be addressed. 

Thumbnail

Sanofi’s $2.9B acquisition of Provention Bio delayed by FTC review

According to Sanofi, it has withdrawn and refiled its premerger notification and report form with the FTC to give the agency more time to review the deal.